This year's ASMS 2021 mass spectrometry conference is a milestone edition for Biognosys. We are proud to be presenting a record number of 3 oral presentations, 1 workshop panel, 10 scientific posters, 2 poster collaborations, and 2 Spectronaut breakfast seminars. We will discuss how our new automated plasma depletion pipeline led to a +362% increase of true leads and introduce our semi-automated workflow to robustly identify 10,000+ unique immunopeptides from low amounts of cultured cells and tissue samples.

We will be at HUPO 2021 on Nov 15-19th with two scientific poster presentations on biofluid biomarker discovery and a live industry seminar focused on the launch of SpectroMine 3, our software solution with unsurpassed performance for DDA proteomics.

We are honored to support Cancer Scout, a large-scale multi-omics research project to accelerate personalized cancer medicine. It is jointly led by The University Medical Center Göttingen and Siemens Healthineers. The project combines genomics, proteomics, and pathology data through artificial intelligence into a "digital biopsy" that supports early, accurate cancer diagnosis and treatment.

We are pleased to announce the extension of our strategic partnership with Indivumed, combining our capabilities in omics research to provide biopharma customers with immunopeptidomics insights for drug discovery. Biognosys' proprietary technology and software enables the identification of over 10,000 unique immunopeptides from low amounts of sample material.